SYBLEU INC.
SYBLEU INC. intends to engage in the primarily in the acquisition, licensing, and development of regenerative medical applications. It develops medical applications up to the point of completion of Phase I and or Phase II clinical trials after which the company sell or license developed applications or advance the application to Phase III clinical trials. SYBLEU INC. was incorporated in 2020 and … Read more
SYBLEU INC. (SYBE) - Net Assets
Latest net assets as of December 2023: $-389.96K USD
Based on the latest financial reports, SYBLEU INC. (SYBE) has net assets worth $-389.96K USD as of December 2023.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($304.15K) and total liabilities ($694.11K). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-389.96K |
| % of Total Assets | -128.21% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
SYBLEU INC. - Net Assets Trend (2019–2022)
This chart illustrates how SYBLEU INC.'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for SYBLEU INC. (2019–2022)
The table below shows the annual net assets of SYBLEU INC. from 2019 to 2022.
| Year | Net Assets | Change |
|---|---|---|
| 2022-12-31 | $-266.08K | -6.45% |
| 2021-12-31 | $-249.96K | -5317.43% |
| 2020-12-31 | $-4.61K | -66.03% |
| 2019-12-31 | $-2.78K | -- |
Equity Component Analysis
This analysis shows how different components contribute to SYBLEU INC.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 38546900.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2022)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $1.03K | % |
| Other Components | $122.21K | % |
| Total Equity | $-266.08K | 100.00% |
SYBLEU INC. Competitors by Market Cap
The table below lists competitors of SYBLEU INC. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
HEALTHSTREAM (HL5.SG)
STU:HL5
|
$168.05K |
|
CREDIT AGRICOLE - Dusseldorf Stock Exchang
DU:XCA
|
$168.18K |
|
Mexus Gold Us
PINK:MXSG
|
$168.22K |
|
JC DECAUX - Dusseldorf Stock Exchang
DU:DCS
|
$168.33K |
|
ORANGE (FTE.SG)
STU:FTE
|
$167.89K |
|
Ivory Properties Group Bhd
KLSE:5175
|
$167.70K |
|
HUDBAY MINERALS (OCKA.SG)
STU:OCKA
|
$167.60K |
|
Eldav-L
TA:ELDAV
|
$167.48K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in SYBLEU INC.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2021 to 2022, total equity changed from -249,960 to -266,083, a change of -16,123.
- Net loss of 180,304 reduced equity.
- Other factors increased equity by 164,181.
Equity Change Factors (2021 to 2022)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-180.30K | -67.76% |
| Other Changes | $164.18K | +61.7% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares SYBLEU INC.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | $0.00 | $0.06 | x |
| 2020-12-31 | $0.00 | $0.06 | x |
| 2021-12-31 | $-0.02 | $0.06 | x |
| 2022-12-31 | $-0.03 | $0.06 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently SYBLEU INC. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -1541.59%
- • Asset Turnover: 0.19x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is below the historical average (0.00%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | 0.00% | 0.00% | 0.00x | 0.00x | $-46.03K |
| 2020 | 0.00% | -2513.47% | 0.02x | 0.00x | $-101.38K |
| 2021 | 0.00% | -2096.98% | 0.15x | 0.00x | $-220.35K |
| 2022 | 0.00% | -1541.59% | 0.19x | 0.00x | $-153.70K |
Industry Comparison
This section compares SYBLEU INC.'s net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| SYBLEU INC. (SYBE) | $-389.96K | 0.00% | N/A | $167.95K |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |